Article
Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2017
Iijima Yuki, Hirotsu Yosuke, Amemiya Kenji, Ooka Yoshihiko, Mochizuki Hitoshi, Oyama Toshio, Nakagomi Takahiro, Uchida Yoshinori, Kobayashi Yoichi, Tsutsui Toshiharu, Kakizaki Yumiko, Goto Taichiro, Miyashita Yoshihiro, Omata Masao
Abstract excerpt
INTRODUCTION: Immunotherapy has become a treatment option for lung cancer. The utility of nivolumab as second-line treatment for non-small cell lung cancer has been proven, but predictive biomarkers influencing its efficacy remain unknown. METHODS: This study involved 14 patients who were treated with nivolumab from February 1 to September 30, 2016. The early response of the level of circulating tumour DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.